H. Lundbeck A/S has planned the following dates in 2011 for the financial statements, the Annual General Meeting and payment of annual dividend. 24 February 2011 Annual report 2010 30 March 2011 Annual General Meeting 5 April 2011 Payment of annual dividend 4 May 2011 Interim report for the first quarter of 2011 10 August 2011 Interim report for the second quarter of 2011 9 November 2011 Interim report for the third quarter of 2011 Lundbeck contacts Investors: Media: Palle Holm Olesen Mads Kronborg Chief Specialist, Investor Relations Media Relations Manager +45 36 43 24 26 +45 36 43 28 51 Magnus Thorstholm Jensen Stine Hove Marsling Investor Relations Officer External Communication Specialist +45 36 43 38 16 +45 36 43 28 33 Jacob Tolstrup Vice President +1 847 282 5713 About Lundbeck H. Lundbeck A/S (LUN.CO, LUN DC, HLUKY) is an international pharmaceutical company highly committed to improving the quality of life for people suffering from central nervous system (CNS) disorders. For this purpose, Lundbeck is engaged in the research and development, production, marketing and sale of pharmaceuticals across the world. The company's products are targeted at disorders such as depression and anxiety, schizophrenia, insomnia, epilepsy and Huntington's, Alzheimer's and Parkinson's diseases. Lundbeck was founded in 1915 by Hans Lundbeck in Copenhagen, Denmark. Today Lundbeck employs approximately 5,900 people worldwide. Lundbeck is one of the world's leading pharmaceutical companies working with CNS disorders. In 2009, the company's revenue was DKK 13.7 billion (approximately EUR 1.8 billion or USD 2.6 billion). For more information, please visit www.lundbeck.com. [HUG#1464705]